Navigation Links
New Mesothelioma Treatment Shows Promise
Date:3/22/2010

Non-toxic vaccine clinical trial, funded by the Mesothelioma Applied Research Foundation, publishes successful results for mesothelioma treatment.

(PRWEB) March 22, 2010 -- A new dendritic cell-based immunotherapy has been demonstrated in clinical trial to be well-tolerated and capable of inducing an immunological response against mesothelioma cells in patients.

In the study, funded by the Mesothelioma Applied Research Foundation and just published in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine, researchers administered three vaccinations of clinical-grade autologous dendritic cells to ten pleural mesothelioma patients. Distinct immunological responses, with moderate fever as the only side-effect, and with no evidence of autoimmunity or severe toxicities, mark an important milestone in mesothelioma research.

“For the past several years, aggressive chemotherapy has been utilized as an often effective, but difficult-to-tolerate, drug regimen for mesothelioma treatment. The prospect of adding to our arsenal other effective, but less toxic and better-tolerated, treatments will broaden greatly our ability to treat patients,” says Mary Hesdorffer, NP, Medical Liaison for the Mesothelioma Applied Research Foundation.

Joachim G. Aerts, a co-author of the research study and pulmonary physician at Erasmus Medical Center in the Netherlands, says: “We hope that by further development of our method it will be possible to increase survival in patients with mesothelioma and eventually vaccinate persons who have been in contact with asbestos to prevent them from getting asbestos-related diseases.”

Mesothelioma is a malignant tumor of the lining of the lung, abdomen or heart caused by asbestos. Medical experts consider it one of the most aggressive of all cancers. For decades it was regarded as untreatable, deadly and hopeless; and so, in a sad, self-fulfilling prophecy, the need for research to develop effective treatments was mostly ignored. For the Mesothelioma Applied Research Foundation and today’s patients, their families, and the millions of Americans who in the last five decades have been exposed to asbestos and are at risk for the cancer, this is unacceptable.

The Mesothelioma Applied Research Foundation is the national non-profit dedicated to finding a cure for mesothelioma by funding research, providing education and support for patients, and leading advocacy efforts for a national commitment to end the mesothelioma tragedy. The Foundation hosts the annual International Symposium on Malignant Mesothelioma, which unites doctors, researchers, patients and families, legal advocates, union representatives and other concerned individuals to share information and advance mesothelioma research. For more information visit www.curemeso.org.

###

Read the full story at http://www.prweb.com/releases/2010/03/prweb3758744.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Mesocare.org Presents “Ask the Expert” for Mesothelioma Patients and Their Families
2. Sokolove Law's MesoRC Site Serves Illinois Mesothelioma Patients and their Families
3. Attorney Joe Belluck Hails Department Of Defense For Increased Funding Of Mesothelioma Research
4. Advancing Mesothelioma Research
5. Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options
6. Possible vaccine for mesothelioma proven safe
7. U.K.: Justice for Asbestos Disease Victims Requires Mesothelioma Research Funding
8. National Asbestos Lawyers of Cooney Conway Launches Mesothelioma Portal
9. Steroids May Be Overrated in Treatment of COPD
10. Experimental stem cell treatment arrests acute lung injury in mice, study shows
11. Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Mesothelioma Treatment Shows Promise 
(Date:8/16/2017)... ... August 16, 2017 , ... ... affiliations and de novo development, today announced Cumberland Skin Surgery and Dermatology ... Surgery and Dermatology, with offices in both Hermitage and Lebanon, Tennessee, provides comprehensive ...
(Date:8/16/2017)... ... 2017 , ... Paul Vitenas, MD, FACS , is honored to announce ... list identifies the nation’s top physicians, in a variety of specialties. This marks the ... of Castle Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider of ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of ... every reprocessing cycle, both between patient procedures and before storage, is a requisite ... as important to the prevention of disease transmission and nosocomial infection as cleaning ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... $5.99, eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery ... of God's love, and all the many ways God shows love to those ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... an opportunity for men and women to train as hospice volunteers. Volunteers provide ... life-limiting illness. For over 30 years, the agency has trained volunteers to be ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... Tenn. , July 31, 2017 Three Tru-D SmartUVC ... Yongsan, South Korea . Tru-D, short for "Total Room ... and operating rooms after an environmental services (ES) professional cleans the area ... ... "Although the ...
(Date:7/28/2017)... 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... ended June 30, 2017, and updated its financial outlook ... For the fiscal third quarter, Hill-Rom reported earnings ... diluted share in the prior-year period. These results reflect ... diluted share primarily related to the non-cash write-down of ...
(Date:7/27/2017)... WARSAW, Ind., July 27, 2017  Zimmer Biomet Holdings, ... the quarter ended June 30, 2017.  The Company reported ... of 1.1% over the prior year period, and an ... approximately 240 basis points of contribution from the LDR ... from the second quarter of 2016, or 0.3% on ...
Breaking Medicine Technology: